Literature DB >> 27217859

Diagnosis, referral, and primary treatment decisions in newly diagnosed prostate cancer patients in a multidisciplinary diagnostic assessment program.

David Guy1, Gabriella Ghanem1, Andrew Loblaw2, Roger Buckley3, Beverly Persaud3, Patrick Cheung4, Hans Chung4, Cyril Danjoux4, Gerard Morton4, Jeff Noakes3, Les Spevack3, David Hajek3, Stanley Flax3.   

Abstract

INTRODUCTION: We aimed to report on data from the multidisciplinary diagnostic assessment program (DAP) at the Gale and Graham Wright Prostate Centre (GGWPC) at North York General Hospital (NYGH). We assessed referral, diagnosis, and treatment decisions for newly diagnosed prostate cancer (PCa) patients as seen over time, risk stratification, and clinic type to establish a deeper understanding of current decision-making trends.
METHODS: From June 2007 to April 2012, 1277 patients who were diagnosed with PCa at the GGWPC were included in this study. Data was collected and reviewed retrospectively using electronic patient records.
RESULTS: 1031 of 1260 patients (81.8%) were seen in a multidisciplinary clinic (MDC). Over time, a decrease in low-risk (LR) diagnoses and an increase intermediate-risk (IR) diagnoses was observed (p<0.0001). With respect to overall treatment decisions 474 (37.1%) of patients received primary radiotherapy, 340 (26.6%) received surgical therapy, and 426 (33.4%) had conservative management; 57% of patients who were candidates for active surveillance were managed this way. No significant treatment trends were observed over time (p=0.8440). Significantly, different management decisions were made in those who attended the MDC compared to those who only saw a urologist (p<0.0001).
CONCLUSIONS: In our DAP, the vast majority of patients presented with screen-detected disease, but there was a gradual shift from low- to intermediate-risk disease over time. Timely multidisciplinary consultation was achievable in over 80% of patients and was associated with different management decisions. We recommend that all patients at risk for prostate cancer be worked up in a multi-disciplinary DAP.

Entities:  

Year:  2016        PMID: 27217859      PMCID: PMC4839993          DOI: 10.5489/cuaj.3510

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


  20 in total

Review 1.  The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.

Authors:  Jonathan I Epstein; William C Allsbrook; Mahul B Amin; Lars L Egevad
Journal:  Am J Surg Pathol       Date:  2005-09       Impact factor: 6.394

2.  Canadian prostate brachytherapy in 2012.

Authors:  Mira Keyes; Juanita Crook; W James Morris; Gerard Morton; Tom Pickles; Nawaid Usmani; Eric Vigneault
Journal:  Can Urol Assoc J       Date:  2013 Jan-Feb       Impact factor: 1.862

Review 3.  Controversies in prostate cancer radiotherapy: consensus development.

Authors:  H Lukka; P Warde; T Pickles; G Morton; M Brundage; L Souhami
Journal:  Can J Urol       Date:  2001-08       Impact factor: 1.344

4.  Dramatic increase in prostate cancer cases by 2021.

Authors:  Harvey Quon; Andrew Loblaw; Robert Nam
Journal:  BJU Int       Date:  2011-04-20       Impact factor: 5.588

5.  Long-term follow-up of a large active surveillance cohort of patients with prostate cancer.

Authors:  Laurence Klotz; Danny Vesprini; Perakaa Sethukavalan; Vibhuti Jethava; Liying Zhang; Suneil Jain; Toshihiro Yamamoto; Alexandre Mamedov; Andrew Loblaw
Journal:  J Clin Oncol       Date:  2014-12-15       Impact factor: 44.544

6.  Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.

Authors:  Anders Widmark; Olbjørn Klepp; Arne Solberg; Jan-Erik Damber; Anders Angelsen; Per Fransson; Jo-Asmund Lund; Ilker Tasdemir; Morten Hoyer; Fredrik Wiklund; Sophie D Fosså
Journal:  Lancet       Date:  2008-12-16       Impact factor: 79.321

7.  A multidisciplinary prostate cancer clinic for newly diagnosed patients: developing the role of the advanced practice nurse.

Authors:  Lydia T Madsen; Catherine Craig; Deborah Kuban
Journal:  Clin J Oncol Nurs       Date:  2009-06       Impact factor: 1.027

8.  Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer.

Authors:  Laurence Klotz; Liying Zhang; Adam Lam; Robert Nam; Alexandre Mamedov; Andrew Loblaw
Journal:  J Clin Oncol       Date:  2009-11-16       Impact factor: 44.544

9.  Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.

Authors:  Padraig Warde; Malcolm Mason; Keyue Ding; Peter Kirkbride; Michael Brundage; Richard Cowan; Mary Gospodarowicz; Karen Sanders; Edmund Kostashuk; Greg Swanson; Jim Barber; Andrea Hiltz; Mahesh K B Parmar; Jinka Sathya; John Anderson; Charles Hayter; John Hetherington; Matthew R Sydes; Wendy Parulekar
Journal:  Lancet       Date:  2011-11-02       Impact factor: 79.321

10.  Acceptability and preliminary feasibility of an internet/CD-ROM-based education and decision program for early-stage prostate cancer patients: randomized pilot study.

Authors:  Michael A Diefenbach; Nihal E Mohamed; Brian P Butz; Natan Bar-Chama; Richard Stock; Jamie Cesaretti; Waleed Hassan; David Samadi; Simon J Hall
Journal:  J Med Internet Res       Date:  2012-01-13       Impact factor: 5.428

View more
  4 in total

Review 1.  Prolaris Cell Cycle Progression Test for Localized Prostate Cancer: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2017-05-01

2.  Construction of a fusion plasmid containing the PSCA gene and cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and its anti-tumor effect in an animal model of prostate cancer.

Authors:  T J Mai; R Ma; Z Li; S C Bi
Journal:  Braz J Med Biol Res       Date:  2016-10-24       Impact factor: 2.590

Review 3.  Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility.

Authors:  E David Crawford; Neal D Shore; Daniel P Petrylak; Celestia S Higano; Charles J Ryan
Journal:  Ther Adv Med Oncol       Date:  2017-03-22       Impact factor: 8.168

Review 4.  Rethinking prostate cancer screening: could MRI be an alternative screening test?

Authors:  David Eldred-Evans; Henry Tam; Heminder Sokhi; Anwar R Padhani; Mathias Winkler; Hashim U Ahmed
Journal:  Nat Rev Urol       Date:  2020-07-21       Impact factor: 14.432

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.